Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Net Income towards Common Stockholders: 2016-2025

Historic Net Income towards Common Stockholders for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$50.3 million.

  • Rocket Pharmaceuticals' Net Income towards Common Stockholders rose 24.56% to -$50.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$240.9 million, marking a year-over-year increase of 6.65%. This contributed to the annual value of -$258.7 million for FY2024, which is 5.35% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Net Income towards Common Stockholders of -$50.3 million as of Q3 2025, which was up 26.97% from -$68.9 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of -$34.5 million in Q2 2021 and a low of -$69.6 million during Q2 2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$62.3 million, with a median of -$61.9 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Rocket Pharmaceuticals' Net Income towards Common Stockholders was 27.36% (2021), while the steepest drop was 72.35% (2021).
  • Rocket Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$44.2 million in 2021, then slumped by 50.80% to -$66.7 million in 2022, then rose by 10.59% to -$59.7 million in 2023, then dropped by 1.12% to -$60.3 million in 2024, then grew by 24.56% to -$50.3 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$50.3 million for Q3 2025, versus -$68.9 million for Q2 2025 and -$61.3 million for Q1 2025.